Aureka Biotechnologies completes USD 35 million Series A+ financing to accelerate construction of next-generation Tech-Bio agent infrastructure

Recently, a tech-bio company focused on agent-driven antibody drug development, Aureka Biotechnologies, announced the completion of a USD 35 million Series A+ financing round. This round was led by HSG, with participation from MPCi, BioTrack Capital, and continued investment from existing shareholders including 5Y Capital, Qiming Venture Partners, and NRL Capital. To date, Aureka Biotechnologies has completed Series A and Series A+ financing rounds totaling nearly USD 100 million.

The funds from this round will be primarily used to advance the development of Aureka Biotechnologies' proprietary innovative functional antibody design platform, AuraIDE™, to strengthen foundational model and agent capabilities, to enhance high-throughput and high-content experimental platform infrastructure, to further integrate the key steps of the agent from project initiation and molecular design to drug development and translational implementation, and to accelerate the transition of diversified innovative drug pipelines into clinical stages.

Centered on the core mission of de novo functional antibody design, Aureka Biotechnologies is building a customized high-throughput and high-content experimental infrastructure to support its generative antibody design system, enhancing the evolutionary efficiency of model and process iteration, and scaling up the production of differentiated, high-value innovative functional antibodies.

By integrating high-throughput single-cell functional screening with synthetic biology evolution systems, Aureka Biotechnologies continues to reshape the approach to acquiring functional data, establishing a data foundation characterized by both high throughput and high information density. This supports continuous model learning and optimization, and continually expands the models' generalization boundaries and directed optimization capabilities across complex targets, mechanisms, and indications. The company is making precise deployments in multiple high-value and high-challenge areas, including multispecific antibodies (AURA083), agonistic antibodies (AURA104, AURA105), highly efficient internalizing antibodies (AURA136), pH-switch antibodies (AURA053), and epitope-specific targeting antibodies (AURA010, AURA012, AURA014). One drug candidate is about to enter the clinical stage, two are in IND-enabling development, and the company has already attracted sustained interest and collaborative engagement from multiple global top-tier pharmaceutical companies.

Aureka Biotechnologies continues to advance collaborative research and development projects with multiple multinational pharmaceutical companies, engaging in in-depth cooperation around complex targets and functional mechanisms, and is progressively moving from project-based collaboration to value co-creation and transaction-driven transformation at the molecular level.

Over the past two years, Aureka Biotechnologies has achieved tens of millions of U.S. dollars in commercial revenue, and through continued delivery, has validated the capability advantages of its research and development system in complex molecular design and functional realization. With multiple pipeline candidates advancing into key preclinical stages, Aureka Biotechnologies is steadily building a translational pathway from molecular design and functional validation to out-licensing transactions, and its commercialization capabilities are entering a phase of accelerated release.